Free Trial

INmune Bio (INMB) Stock Price, News & Analysis

INmune Bio logo
$2.20 -0.11 (-4.55%)
As of 10:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About INmune Bio Stock (NASDAQ:INMB)

Key Stats

Today's Range
$2.22
$2.33
50-Day Range
$2.09
$8.09
52-Week Range
$1.89
$11.64
Volume
390,826 shs
Average Volume
818,379 shs
Market Capitalization
$51.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.40
Consensus Rating
Moderate Buy

Company Overview

INmune Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

INMB MarketRank™: 

INmune Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 616th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    INmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    INmune Bio has only been the subject of 4 research reports in the past 90 days.

  • Read more about INmune Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for INmune Bio are expected to grow in the coming year, from ($2.24) to ($1.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of INmune Bio is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of INmune Bio is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    INmune Bio has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about INmune Bio's valuation and earnings.
  • Percentage of Shares Shorted

    68.78% of the float of INmune Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    INmune Bio has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in INmune Bio has recently increased by 43.66%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    INmune Bio does not currently pay a dividend.

  • Dividend Growth

    INmune Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    68.78% of the float of INmune Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    INmune Bio has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in INmune Bio has recently increased by 43.66%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    INmune Bio has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for INmune Bio this week, compared to 3 articles on an average week.
  • Search Interest

    28 people have searched for INMB on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, INmune Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.70% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.72% of the stock of INmune Bio is held by institutions.

  • Read more about INmune Bio's insider trading history.
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INMB Stock News Headlines

The Next Commodity Crisis Just Got a Name: Silver
Elon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to SpaceX to AI. And now, whispers are growing that his next move could be in silver. Why? Because silver is the lifeblood of EVs, solar panels, and AI tech.
Scotiabank Downgrades INmune Bio (INMB)
INmune Bio: What's Left For Investors
See More Headlines

INMB Stock Analysis - Frequently Asked Questions

INmune Bio's stock was trading at $4.67 at the beginning of 2025. Since then, INMB shares have decreased by 51.9% and is now trading at $2.2450.

INmune Bio, Inc. (NASDAQ:INMB) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43). The company earned $0.05 million during the quarter.
Read the conference call transcript
.

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

Last Earnings
5/08/2025
Today
7/13/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INMB
CIK
1711754
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$23.00
Low Price Target
$8.00
Potential Upside/Downside
+696.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.08 million
Net Margins
N/A
Pretax Margin
-81,592.01%
Return on Equity
-119.35%
Return on Assets
-89.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.64
Quick Ratio
2.64

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
5,446.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.45 per share
Price / Book
1.59

Miscellaneous

Outstanding Shares
23,580,000
Free Float
15,165,000
Market Cap
$54.47 million
Optionable
Optionable
Beta
1.34
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:INMB) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners